We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 12, 2021

PD-L1 Tumor Proportion Score and OS From First-Line Pembrolizumab for Nonsquamous vs Squamous NSCLC

Journal of Thoracic Oncology


Additional Info

Journal of Thoracic Oncology
PD-L1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous Non-Small Cell Lung Cancer
J Thorac Oncol 2021 Aug 26;[EPub Ahead of Print], DB Doroshow, W Wei, S Gupta, J Zugazagoitia, C Robbins, B Adamson, DL Rimm

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading